Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,090 across all filing types
Latest filing 2017-07-31 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
首次公开发行股票并在创业板上市上市公告书提示性公告
Regulatory Filings Classification · 95% confidence The document is a listing announcement for Xiamen Aide Biomedical Technology Co., Ltd. regarding its initial public offering (IPO) and listing on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It includes details such as stock code, total shares after IPO, shares issued, and risk warnings. The document is relatively short (1585 characters) and serves as a public notice rather than a detailed financial report or prospectus. It explicitly states that the full listing prospectus and IPO documents are available on official disclosure websites, indicating this document is an announcement rather than the full report itself. Therefore, it fits best under the category of a Regulatory Filing (RNS) as a general regulatory announcement about the IPO and listing, not a full Annual Report, Capital Update, or other specific report type.
2017-07-31 Chinese
首次公开发行股票并在创业板上市网上发行结果公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the results of an initial public offering (IPO) of shares by Xiamen Aide Biomedical Technology Co., Ltd. It details the number of shares issued, pricing, subscription results, and underwriting information. The document does not contain financial statements or detailed financial analysis but rather provides an update on the capital raising event and share issuance. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is short and focused on the issuance results, not a full report or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2017-07-27 Chinese
首次公开发行股票并在创业板上市网上摇号中签结果公告
Capital/Financing Update Classification · 95% confidence The document is an announcement of the lottery results for the initial public offering (IPO) stock subscription of Xiamen Aide Biomedical Technology Co., Ltd. It details the winning numbers for the online lottery, instructions for investors to check their results, and payment obligations. The document is short (1294 characters) and focuses on the outcome of the stock issuance lottery rather than the issuance itself or financial details. This fits the category of a Capital/Financing Update (CAP) as it relates to the company's fundraising activity through stock issuance and the announcement of subscription results.
2017-07-25 Chinese
首次公开发行股票并在创业板上市网上申购情况及中签率公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the initial public offering (IPO) of shares by Xiamen Aide Biomedical Technology Co., Ltd., including details about the online subscription situation and the lottery winning rate. It provides information about the subscription process, pricing, and payment obligations for investors. The document is short (1298 characters) and focuses on the subscription and allocation results of the IPO shares, which is a capital raising event. This fits the category of Capital/Financing Update (CAP) as it relates to the company's fundraising activities and share issuance process. It is not a full financial report, earnings release, or regulatory filing, but a specific update on the capital issuance process.
2017-07-24 Chinese
首次公开发行股票并在创业板上市投资风险特别公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) of shares by Xiamen Aide Biomedical Technology Co., Ltd. It includes information about the issuance process, pricing, subscription rules, investment risks, and regulatory approvals. The text is not a financial report or earnings release but a special risk announcement related to the IPO. It does not contain financial statements or management discussion but focuses on informing investors about the risks and procedures of the stock issuance and listing on the Growth Enterprise Market (创业板). This type of document fits best under Capital/Financing Update (CAP) as it relates to fundraising and capital structure changes through the IPO process.
2017-07-20 Chinese
首次公开发行股票并在创业板上市发行公告
Regulatory Filings
2017-07-20 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.